Bimekizumab resistance management

Bimekizumab (Bimekizumab) is the latest IL-17 inhibitor. It is a humanized monoclonal immunoglobulin IgG1 antibody that works by neutralizing IL-17A and IL-17F. It shows a unique mechanism of action that is different from ixekizumab and secukinumab (selective IL17A inhibitors) and brodalumab (IL17 receptor antagonist). Several Phase II and III clinical trials reported the efficacy and safety of bimeclizumab, with significantly higher efficacy even over longer periods of time.

If a patient develops resistance to mezumab, doctors will evaluate whether the patient is actually resistant to mezumab, which can be determined by examining the patient for resistance gene mutations or other resistance-related factors. Sometimes, adjusting the dose or frequency of bimeclizumab can help control resistance. This may require evaluation and adjustment by the physician based on the patient's specific situation. Another way to deal with drug resistance is to use combination therapy. Unlike a single drug, the combined use of multiple drugs may improve treatment efficacy and reduce the occurrence of drug resistance.

The generic drug Bimeizumab has not yet been launched in the country, so it cannot be included in medical insurance. The European version of bimezumab original drug sold overseas, specifications160mg*2 per box may cost more than 40,000 yuan (the price may fluctuate due to the exchange rate). The price is still relatively high. There is currently no generic version of bimezumab produced and launched. For the specific price and drug information of this drug, please consult a medical consultant.